CRISPR Therapeutics AG
- Stock
- Ticker CRSP
- ISIN CH0334081137
- Nasdaq
- US listing in dollars
Performance, volatility and drawdowns of CRISPR Therapeutics AG since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $18,798. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −85.1% in 04/2025, measured from the peak in 01/2021. The old peak has not been reached again yet.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 36 | 0.9 | 0.9 | 0.9 | 0.9 | 1.5 | 10 | 13 |
| Operating income | -65 | -148 | -229 | -132 | -155 | -130 | -117 | -130 |
| EBITDA | -60 | -144 | -225 | -128 | -149 | -126 | -113 | -126 |
| Net income | -37 | -136 | -209 | -106 | -131 | -123 | -91 | -111 |
| Earnings per share | -0.42 | -1.58 | -2.40 | -1.17 | -1.35 | -1.28 | -0.94 | -1.15 |
| Balance sheet | ||||||||
| Total assets | 2,242 | 2,166 | 2,030 | 2,245 | 2,265 | 2,726 | 2,651 | 2,556 |
| Liabilities | 310 | 337 | 319 | 329 | 343 | 911 | 904 | 908 |
| Equity | 1,932 | 1,829 | 1,711 | 1,916 | 1,922 | 1,815 | 1,747 | 1,648 |
| Cash | 298 | 235 | 194 | 286 | 348 | 423 | 291 | 192 |
| Long-term debt | – | – | – | – | 0.0 | 585 | 586 | 587 |
| Cash flow | ||||||||
| Operating cash flow | -50 | -54 | -114 | -85 | -93 | -109 | -83 | -90 |
| Capital expenditure | -0.3 | -0.2 | -0.1 | -0.1 | -0.5 | -0.5 | -0.6 | -0.4 |
| Free cash flow | -50 | -54 | -114 | -85 | -93 | -109 | -84 | -90 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2020 at +151.4%, weakest 2021 at −50.5%. 6 of 9 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 2 Nov 2026 | −$1.15 |
| 3 Aug 2026 | −$0.94 |
| 4 May 2026 | −$1.28 |
| 12 Feb 2026 | −$1.35 |
| 10 Nov 2025 | −$1.17 |
| 4 Aug 2025 | −$2.40 |
| 6 May 2025 | −$1.58 |
| 11 Feb 2025 | −$0.42 |
| 5 Nov 2024 | −$1.01 |
| 5 Aug 2024 | −$1.49 |
| 8 May 2024 | −$1.43 |
| 21 Feb 2024 | $1.13 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €3.4bn
- Market cap in trading currency
- $3.79bn
- Enterprise value
- $2.11bn
- P/E
- –
- P/S
- 150.67
- P/B
- 2.30
- EV/Sales
- 83.71
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -9.9%
Results (last four quarters)
- Revenue
- $25.2m
- Gross profit
- –
- EBITDA
- −$514m
- Net income
- −$456m
- Earnings per share
- −$4.72
- Revenue per share
- $0.26
- Revenue growth
- +1,325.1%
- Earnings growth
- –
Profitability
- Gross margin
- –
- Operating margin
- -2,114.8%
- Net margin
- -1,812.1%
- Return on equity
- -25.6%
- Return on assets
- -17.8%
Balance sheet and cash flow
- Cash
- $2.27bn
- Cash per share
- $23.43
- Financial debt
- $587m
- Debt/equity %
- 36
- Current ratio
- 16.21
- Book value per share
- $16.99
- Operating cash flow
- −$375m
- Free cash flow
- −$377m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 97.0m
- Volume
- 3.32m
- Avg. volume 3 months
- 1.65m
- Relative volume
- 1.9
Price and technicals
- Price
- $39.10
- 1 day
- +0.4%
- 52-week high
- $61.89
- 52-week low
- $38.93
- Distance to 52-week high
- −36.8%
- Distance to 52-week low
- +0.4%
- Distance to 50-day line
- −22.9%
- Distance to 200-day line
- −25.2%
- RSI (14)
- 28
- Volatility 1M
- 62.7%
Performance
- 1 week
- −7.4%
- 1 month
- −21.8%
- 3 months
- −31.5%
- 6 months
- −22.4%
- YTD
- −25.4%
- 1 year
- −22.9%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has CRSP performed since 11/2016?
$10,000 grew to $18,798 by 20 Nov 2026, which is +6.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is CRSP?
Volatility was 67.0% per year, measured on monthly returns. The largest decline from a peak was −85.1%, with the low in 04/2025.
How does CRSP compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CRSP returned +6.5% at 67.0%. The correlation of monthly returns was 0.47; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.
Why does this page show a US listing?
The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.